Retatrutide — For women: everything you need to know about appetite

Introduction

In this reference guide, we explore Retatrutide (Triple agonist GLP-1 · GIP · Glucagon) to help you make an informed choice based on current science and user feedback.

Next-generation peptide studied for weight management and glycemic control. Specific considerations for women, including cycle and menopause.

Key benefits

Here are the most documented benefits of Retatrutide in relation to appetite:

• Significant reduction in appetite and food noise
• Improved insulin sensitivity
• Progressive, sustained weight loss in clinical studies
• Better postprandial glycemic control
• Reduction in visceral fat linked to cardiometabolic risk
• Triple effect (GLP-1, GIP, Glucagon) outperforming mono-agonists

How it works

Retatrutide acts simultaneously on three key metabolic receptors: GLP-1, GIP and Glucagon. This triple activation creates a synergistic effect that mono-agonists cannot reproduce.

GLP-1 agonism slows gastric emptying and increases satiety. The GIP receptor improves postprandial insulin response. The glucagon receptor increases resting energy expenditure, setting Retatrutide apart from semaglutide or tirzepatide.

Phase 2 studies published in the New England Journal of Medicine in 2023 showed average weight loss of 17.5% to 24.2% depending on dose over 48 weeks — an unprecedented result for non-surgical pharmacological treatment.

Related product

Retatrutide — Triple agonist GLP-1 · GIP · Glucagon

Next-generation peptide studied for weight management and glycemic control.

Visit the store →

Usage protocol

Published protocols typically start at a low dose (2 mg/week) and increase every 4 weeks up to the individualized target dose.

Injection is subcutaneous, once weekly, ideally on the same day and time to stabilize plasma levels.

Gradual titration minimizes digestive side effects (nausea, excess satiety) common with GLP-1 agonists.

Expected results

User feedback converges: initial effects in the first weeks, then amplification over 8 to 12 weeks. Protocol consistency remains the number one factor for lasting results on appetite.

Safety and precautions

The most common side effects are digestive and usually transient. Gradual titration and adequate hydration reduce their intensity. People with diabetes, pancreatitis history or who are pregnant should consult a healthcare professional before use.